Status:
COMPLETED
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Lead Sponsor:
Pfizer
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This protocol allows subjects who have participated in a previous SU011248 protocol the ability to continue to receive SU011248 after their study has ended.
Eligibility Criteria
Inclusion
- Participation in a previous SU011248 protocol and are judged by the investigator to have the potential to derive clinical benefit by remaining on SU011248 after the prior protocol ends.
Exclusion
- Severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
123 Patients enrolled
Trial Details
Trial ID
NCT00443534
Start Date
May 1 2006
End Date
December 1 2011
Last Update
May 24 2013
Active Locations (62)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Aurora, Colorado, United States, 80045
2
Pfizer Investigational Site
Littleton, Colorado, United States, 80120
3
Pfizer Investigational Site
Orlando, Florida, United States, 32806
4
Pfizer Investigational Site
Atlanta, Georgia, United States, 30322